Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)
Phase of Trial: Phase IV
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Aliskiren (Primary) ; Candesartan cilexetil
- Indications Kidney disorders
- Focus Therapeutic Use
- Acronyms RASQAL
- 14 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 10 Apr 2013 Planned end date changed from 12 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 10 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01827202).